Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy
Maturitas · 2025-02 · 193 · 108159
DOI: 10.1016/j.maturitas.2024.108159 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Maturitas, 2025-02. Verfasst von Marla Shapiro C M und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Quality of Life, Hot Flashes, Menopause. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Toronto, Toronto, ON, Canada.
- Astellas Pharma Global Development, Northbrook, IL, USA.
- Astellas Pharma Inc, Tokyo, Japan.
- Astellas Pharma Europe Ltd, Addlestone, UK.
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Research Center for Reproductive Medicine and Gynecological Endocrinology - Menopause Unit, Fondazione Policlinico…
- Inselspital, Bern, Switzerland.
Zitieren
APA
Shapiro C M, M., Wu, X., Wang, X., Miyazaki, K., Morga, A., Nappi, R. E., Stute, P., Martins, K., & Schaudig, K. (2025). Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy. Maturitas, 193, 108159. https://doi.org/10.1016/j.maturitas.2024.108159
Vancouver
Shapiro C M M, Wu X, Wang X, Miyazaki K, Morga A, Nappi RE, et al. Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy. Maturitas. 2025;193:108159. doi:10.1016/j.maturitas.2024.108159
BibTeX
@article{ShapiroCM2025,
author = {Shapiro C M, Marla and Wu, Xi and Wang, Xuegong and Miyazaki, Kentaro and Morga, Antonia and Nappi, Rossella E and Stute, Petra and Martins, Karla and Schaudig, Katrin},
title = {Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy},
journal = {Maturitas},
year = {2025},
volume = {193},
pages = {108159},
doi = {10.1016/j.maturitas.2024.108159}
}
EUVIMED